P21 vs ARA-290
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: P021, Ac-DGGLAG-NH2
A synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.
Also: Cibinetide, ARA 290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- ARA-290 has stronger research evidence (Phase II/III Trials) compared to P21 (Animal Studies).
Detailed Comparison
| Attribute | P21 | ARA-290 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | P21 acts as a CNTF small-molecule peptide mimetic. It enhances neurogenesis in the hippocampus, reduces tau phosphorylation, inhibits neuroinflammation, and improves synaptic plasticity. Designed to be orally bioavailable. | ARA-290 selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (β common receptor). This receptor is expressed on damaged and inflamed tissues. Activation triggers anti-apoptotic, anti-inflammatory, and tissue-protective pathways without stimulating red blood cell production. |
| Common Dosing | Limited community data available See research protocols | 4 mg daily Once daily |
| Administration | Oral (nasal in some studies) | Subcutaneous injection |
| Typical Duration | Ongoing supplementation in studies | 28-day courses in trials |
| Best Time to Take | Morning | Consistent daily timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show cognitive improvement in Alzheimer's mouse models. Research demonstrates increased neurogenesis, reduced tau pathology, and improved learning/memory. Being developed for Alzheimer's and age-related cognitive decline. | Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals. |
Frequently Asked Questions: P21 vs ARA-290
What is the difference between P21 and ARA-290?
P21 is a cognitive peptide that a synthetic peptide mimetic of cntf (ciliary neurotrophic factor) designed for neurodegenerative disease. promotes neurogenesis and reduces neuroinflammation. ARA-290 is a cognitive peptide that an 11-amino acid peptide derived from erythropoietin (epo) that activates the innate repair receptor. unlike epo, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, P21 or ARA-290?
Neither is universally "better" - the choice depends on your specific goals. P21 is typically used for cognitive purposes, while ARA-290 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can P21 and ARA-290 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using P21 and ARA-290 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of P21 and ARA-290 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.